Anti-staphylococcal activities of lysostaphin and LytM catalytic domain

BMC Microbiology

Volumn 12, Issue , 2012, Pages

  Sabala, Izabela ^a,b   Jonsson, Ing Marie ^c   Tarkowski, Andrej ^c   Bochtler, Matthias ^a,b,d  

^a INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^b MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLYSIN; LYSOSTAPHIN; LYTM PROTEIN; PEPTIDOGLYCAN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ECZEMA; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME STABILITY; EXPERIMENTAL MODEL; IN VITRO STUDY; IN VIVO STUDY; IONIC STRENGTH; MOUSE; NONHUMAN; PH; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN STRUCTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCUS SIMULANS; STAPHYLOCOCCUS SIMULANS BIOVAR STAPHYLOLYTICUS; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOLOGICAL AGENTS; CATALYTIC DOMAIN; DISEASE MODELS, ANIMAL; ECZEMA; ENDOPEPTIDASES; LYSOSTAPHIN; MICE; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS SIMULANS;

EID: 84861807721     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-12-97     Document Type: Article

References (41)

1. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ, Diagn Microbiol Infect Dis 1998 31 3 437 451 10.1016/S0732-8893(98) 80002-3 9635235 (Pubitemid 28318625)
2. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR, J Med Chem 2008 51 7 1981 1990 10.1021/jm800038g 18338841 (Pubitemid 351503251)
3. Bacteriophage endolysins as a novel class of antibacterial agents. Borysowski J, Weber-Dabrowska B, Gorski A, Exp Biol Med (Maywood) 2006 231 4 366 377
4. Molecular properties of lysostaphin, a bacteriolytic agent specific for Staphylococcus aureus. Trayer HR, Buckley CE, J Biol Chem 1970 245 18 4842 4846 5456157
5. Isolation and characterization of autolysis-defective mutants of Staphylococcus aureus created by Tn917-lacZ mutagenesis. Mani N, Tobin P, Jayaswal RK, J Bacteriol 1993 175 5 1493 1499 8095258 (Pubitemid 23081827)
6. Characterization of a chromosomally encoded glycylglycine endopeptidase of Staphylococcus aureus. Ramadurai L, Lockwood KJ, Nadakavukaren MJ, Jayaswal RK, Microbiology 1999 145 Pt 4 801 808 10220159 (Pubitemid 29179196)
7. Cloning, sequence, and expression of the lysostaphin gene from Staphylococcus simulans. Recsei PA, Gruss AD, Novick RP, Proc Natl Acad Sci U S A 1987 84 5 1127 1131 10.1073/pnas.84.5.1127 3547405 (Pubitemid 17027305)
8. The molecular organization of the lysostaphin gene and its sequences repeated in tandem. Heinrich P, Rosenstein R, Bohmer M, Sonner P, Gotz F, Mol Gen Genet 1987 209 3 563 569 10.1007/BF00331163 2828883
9. Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus. Thumm G, Gotz F, Mol Microbiol 1997 23 6 1251 1265 10.1046/j.1365-2958.1997.2911657.x 9106216 (Pubitemid 27122210)
10. MEROPS: the peptidase database. Rawlings ND, Morton FR, Kok CY, Kong J, Barrett AJ, Nucleic Acids Res 2008 36 Database issue 320 325 17991683
11. Similar active sites in lysostaphins and D-Ala-D-Ala metallopeptidases. Bochtler M, Odintsov SG, Marcyjaniak M, Sabala I, Protein Sci 2004 13 4 854 861 10.1110/ps.03515704 15044722 (Pubitemid 38429209)
12. Latent LytM at 1.3A resolution. Odintsov SG, Sabala I, Marcyjaniak M, Bochtler M, J Mol Biol 2004 335 3 775 785 10.1016/j.jmb.2003.11.009 14687573 (Pubitemid 38352819)
13. Cell wall-targeting domain of glycylglycine endopeptidase distinguishes among peptidoglycan cross-bridges. Lu JZ, Fujiwara T, Komatsuzawa H, Sugai M, Sakon J, J Biol Chem 2006 281 1 549 558 16257954 (Pubitemid 43671218)
14. Influence of Lif, the lysostaphin immunity factor, on acceptors of surface proteins and cell wall sorting efficiency in Staphylococcus carnosus. Strauss A, Thumm G, Gotz F, J Bacteriol 1998 180 18 4960 4962 9733703 (Pubitemid 28429388)
15. Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice. Kerr DE, Plaut K, Bramley AJ, Williamson CM, Lax AJ, Moore K, Wells KD, Wall RJ, Nat Biotechnol 2001 19 1 66 70 10.1038/83540 11135555 (Pubitemid 32051959)
16. Lysostaphin in experimental renal infections. Harrison EF, Zygmunt WA, J Bacteriol 1967 93 2 520 524 6020559
17. Lysostaphin treatment of methicillin-resistant staphylococcus aureus keratitis in the rabbit(1). Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ, Am J Ophthalmol 2000 130 4 544 11024447
18. Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Dajcs JJ, Thibodeaux BA, Hume EB, Zheng X, Sloop GD, O'Callaghan RJ, Curr Eye Res 2001 22 6 451 457 10.1076/ceyr.22.6. 451.5486 11584345 (Pubitemid 34253204)
19. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, O'Callaghan RJ, Invest Ophthalmol Vis Sci 2002 43 12 3712 3716 12454041 (Pubitemid 35470609)
20. Lysostaphin: an antistaphylococcal agent. Kumar JK, Appl Microbiol Biotechnol 2008 80 4 555 561 10.1007/s00253-008-1579-y 18607587
21. Staphylococcal antimicrobial peptides: relevant properties and potential biotechnological applications. Bastos MC, Ceotto H, Coelho ML, Nascimento JS, Curr Pharm Biotechnol 2009 10 1 38 61 10.2174/138920109787048580 19149589
22. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF, Antimicrob Agents Chemother 2003 47 11 3407 3414 10.1128/AAC.47.11.3407-3414. 2003 14576095 (Pubitemid 37345697)
23. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization. Shah A, Mond J, Walsh S, Antimicrob Agents Chemother 2004 48 7 2704 2707 10.1128/AAC.48.7.2704-2707.2004 15215130 (Pubitemid 38823446)
24. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. Kokai-Kun JF, Chanturiya T, Mond JJ, J Antimicrob Chemother 2009 64 1 94 100 10.1093/jac/dkp145 19398455
25. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. Kokai-Kun JF, Chanturiya T, Mond JJ, J Antimicrob Chemother 2007 60 5 1051 1059 10.1093/jac/dkm347 17848374 (Pubitemid 47617753)
26. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ, Antimicrob Agents Chemother 2003 47 5 1589 1597 10.1128/AAC.47.5.1589-1597.2003 12709327 (Pubitemid 36548542)
27. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Climo MW, Patron RL, Goldstein BP, Archer GL, Antimicrob Agents Chemother 1998 42 6 1355 1360 9624475 (Pubitemid 28257631)
28. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Kluytmans J, van Belkum A, Verbrugh H, Clin Microbiol Rev 1997 10 3 505 520 9227864 (Pubitemid 27359263)
29. Identification of genes controlled by the essential YycG/YycF two-component system of Staphylococcus aureus. Dubrac S, Msadek T, J Bacteriol 2004 186 4 1175 1181 10.1128/JB.186.4.1175-1181.2004 14762013 (Pubitemid 38209478)
30. Crystal structures of active LytM. Firczuk M, Mucha A, Bochtler M, J Mol Biol 2005 354 3 578 590 10.1016/j.jmb.2005.09.082 16269153 (Pubitemid 41628277)
31. Physiological significance of the peptidoglycan hydrolase, LytM, in Staphylococcus aureus. Singh VK, Carlos MR, Singh K, FEMS Microbiol Lett 2010 311 2 167 175 10.1111/j.1574-6968.2010.02087.x 20738399
32. Molecular cloning, sequencing, and expression of lytM, a unique autolytic gene of Staphylococcus aureus. Ramadurai L, Jayaswal RK, J Bacteriol 1997 179 11 3625 3631 9171409 (Pubitemid 27233002)
33. Comparative proteomic analysis of Staphylococcus aureus strains with differences in resistance to the cell wall-targeting antibiotic vancomycin. Pieper R, Gatlin-Bunai CL, Mongodin EF, Parmar PP, Huang ST, Clark DJ, Fleischmann RD, Gill SR, Peterson SN, Proteomics 2006 6 15 4246 4258 10.1002/pmic.200500764 16826566 (Pubitemid 44277028)
34. Design of a polypeptide FRET substrate that facilitates study of the antimicrobial protease lysostaphin. Bardelang P, Vankemmelbeke M, Zhang Y, Jarvis H, Antoniadou E, Rochette S, Thomas NR, Penfold CN, James R, Biochem J 2009 418 3 615 624 10.1042/BJ20081765 19032148
35. Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus. Grundling A, Schneewind O, J Bacteriol 2006 188 7 2463 2472 10.1128/JB.188.7.2463-2472.2006 16547033
36. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Kusuma CM, Kokai-Kun JF, Antimicrob Agents Chemother 2005 49 8 3256 3263 10.1128/AAC.49.8.3256-3263.2005 16048934 (Pubitemid 41060569)
37. Target cell specificity of a bacteriocin molecule: a C-terminal signal directs lysostaphin to the cell wall of Staphylococcus aureus. Baba T, Schneewind O, EMBO J 1996 15 18 4789 4797 8890152 (Pubitemid 26315789)
38. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Schleifer KH, Kandler O, Bacteriol Rev 1972 36 4 407 477 4568761
39. Immunopathological features of rat Staphylococcus aureus arthritis. Bremell T, Lange S, Holmdahl R, Ryden C, Hansson GK, Tarkowski A, Infect Immun 1994 62 6 2334 2344 8188356 (Pubitemid 24157061)
40. Modulates virulence determinant expression and stress resistance: characterization of a functional rsbU strain derived from Staphylococcus aureus 8325-4. Horsburgh MJ, Aish JL, White IJ, Shaw L, Lithgow JK, Foster SJ, J Bacteriol 2002 184 19 5457 5467 10.1128/JB.184.19.5457-5467.2002 12218034 (Pubitemid 35024393)
41. The N-terminal A domain of fibronectin-binding proteins A and B promotes adhesion of Staphylococcus aureus to elastin. Roche FM, Downer R, Keane F, Speziale P, Park PW, Foster TJ, J Biol Chem 2004 279 37 38433 38440 10.1074/jbc.M402122200 15234962 (Pubitemid 39295994)